Navigation Links
New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
Date:5/23/2014

A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study.

The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study, published in the journal Investigational New Drugs, looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

"An advantage with this drug is it is oral and very effective in a significant number of patients with aggressive lymphoma when used at that dose for 7 days out a 21 day cycle," said hematologist Swaminathan Iyer, M.D., who led the multi-site study.

Drugs commonly used to treat NHL and CLL are chemotherapeutic drugs and some biological targeted agents such as the monoclonal antibodies rituximab, ofatumumab and obinutuzumab with varying degrees of success.

Although about 1/2 of patients participating in the phase I study experienced side effects most of which were manageable events, Iyer said that is not unusual for such biologic (non chemotherapy) drugs.

"The side effects were fairly tolerable in this study," Iyer said. "We would like to see more information from a larger group of patients to fully understand the drug's safety and tolerability for those experiencing the middle-to-later stages of these diseases."

Iyer and his group recommend 50 mg, twice-daily doses of alisertib for the advanced phase trials of the drug, which Iyer says has begun enrollment.

Alisertib is not yet approved for general medical use by the FDA. Its impact on T cell lymphoma is being investigated in a separate, phase III trial for a specific type of lymphoma called the T cell lymphomas. Houston Methodist is a participating study site for that project. Initial phase II reports in these T cell lymphomas showed a 57% response, the highest ever noted for any single agent in this disease entity.


'/>"/>

Contact: David Bricker
dmbricker@houstonmethodist.org
832-667-5811
Houston Methodist
Source:Eurekalert

Related medicine news :

1. Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
2. Novel drug therapy targets aggressive form of non-Hodgkins lymphoma
3. International symposium will address non-Hodgkins lymphoma in the young
4. Inhibition of CDK4 might promote lymphoma development and progression
5. Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
6. Chemo-free treatment a possibility for leukemia/lymphoma
7. Scientists explore promising new option for first line of attack in lymphoma
8. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
9. MedMar Healing Center Co-founder Rafael Hernandez Goes the Distance for Leukemia and Lymphoma Society, Running Three Marathons for Nonprofit Health Organization
10. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
11. Reprogrammed treatment-resistant lymphomas respond to cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... (PRWEB) , ... August 05, 2020 , ... AdventHealth Carrollwood ... for safely reopening for class on Monday, August 12, 2020. AdventHealth provided the school ... spread of COVID-19 in the classroom setting. , “We are taking extra steps ...
(Date:8/5/2020)... (PRWEB) , ... August 05, 2020 , ... ... the animal health industry, as president of the largest veterinarian-owned purchasing Cooperative in ... SANTE ANIMALE in various roles where she gained extensive knowledge and experience in ...
(Date:8/5/2020)... Texas (PRWEB) , ... August 04, 2020 , ... ... older adults living with memory impairment, has announced the Best Memory Care Facilities ... access to experts, facility features and amenities. , According to the ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... in the White House, Google, Amelia Arena, the Phoenix airport, the Mayo Clinic, ... locations. , According to Global Plasma Solutions (GPS), the manufacturers of the system, ...
(Date:7/31/2020)... ... 31, 2020 , ... Today Hinge Health, the top-selling musculoskeletal ... & technical capabilities to cover the full continuum of care in MSK, and ... , Currently, employers interested in truly solving their MSK issues must assemble ...
Breaking Medicine News(10 mins):
(Date:7/31/2020)... ... July 31, 2020 , ... In an informal poll of 150 fans, conducted ... a refreshed Minnesota Twins “Minnie and Paul” logo that is more racially and culturally ... was well before the civil rights movement in the United States. The Minnesota Twins ...
(Date:7/22/2020)... ... July 22, 2020 , ... Local animal nutrition expert, Dr. Anoosh Rakhshandeh, ... new pet food and supplies company – Pet Wants Lubbock. , Pet Wants’ specially-crafted, ... with vitamins and minerals for a complete and balanced diet in every bite. Pet ...
(Date:7/18/2020)... ... , ... A Perspective essay published in Psychosomatics: ... among psychiatrists and other clinicians can affect patient-clinician communication and diminish the quality ... authored by researchers at The Fenway Institute and Massachusetts General Hospital and adds ...
Breaking Medicine Technology: